Apogee Therapeutics, Inc. Payments to Acquire Marketable Securities
Apogee Therapeutics, Inc. (APGE) reported Payments to Acquire Marketable Securities of $736.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Apogee Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $552.75M, a 1066.66% increase year-over-year.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $183.24M, a 86.60% increase year-over-year.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $389.09M, a 542.23% increase year-over-year.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $107.63M, a 54.39% decline year-over-year.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $642.30M, a 1.10% decline from fiscal 2024.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $649.45M, a 113.82% increase from fiscal 2023.
- Apogee Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $303.74M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $552.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $736.00M 10-Q · filed 2026-08-10 | $1.13B derived: sum of 3 quarters · filed 2026-08-10 | $1.23B derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $183.24M 10-Q · filed 2026-05-11 | $572.33M derived: sum of 2 quarters · filed 2026-05-11 | $679.96M derived: sum of 3 quarters · filed 2026-05-11 | $727.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $389.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $496.72M derived: sum of 2 quarters · filed 2026-03-02 | $544.10M derived: sum of 3 quarters · filed 2026-08-10 | $642.30M 10-K · filed 2026-03-02 |
| 2025-09-30 | $107.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $155.01M derived: sum of 2 quarters · filed 2026-08-10 | $253.21M 10-Q · filed 2025-11-10 | $313.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $47.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $145.58M 10-Q · filed 2026-08-10 | $206.16M derived: sum of 3 quarters · filed 2026-08-10 | $442.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $98.20M 10-Q · filed 2026-05-11 | $158.78M derived: sum of 2 quarters · filed 2026-05-11 | $394.79M derived: sum of 3 quarters · filed 2026-05-11 | $621.76M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $60.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $296.59M derived: sum of 2 quarters · filed 2026-03-02 | $523.56M derived: sum of 3 quarters · filed 2026-03-02 | $649.45M 10-K · filed 2026-03-02 |
| 2024-09-30 | $236.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $462.97M derived: sum of 2 quarters · filed 2025-11-10 | $588.87M 10-Q · filed 2025-11-10 | $658.39M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $226.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $352.86M 10-Q · filed 2025-08-11 | $422.38M derived: sum of 3 quarters · filed 2026-03-02 | |
| 2024-03-31 | $125.89M 10-Q · filed 2025-05-12 | $195.42M derived: sum of 2 quarters · filed 2026-03-02 | ||
| 2023-12-31 | $69.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $303.74M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $234.22M 10-Q · filed 2024-11-12 |